

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CONCORD HEALTHCARE GROUP CO., LTD.

美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY THE CONTROLLING SHAREHOLDER OF THE COMPANY

This announcement is made by Concord Healthcare Group Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to the shareholders and potential investors of the Company.

The board of directors (the “**Directors**”) of the Company (the “**Board**”) was informed by Medstar (Shanghai) Enterprise Management Co., LTD (醫學之星(上海)企業管理有限公司) (“**Shanghai Medstar**”), one of the controlling shareholders (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company, that Shanghai Medstar has purchased a total of 45,600 H shares of the Company from the open market for an aggregate consideration of HK\$311,904.00 at the price of HK\$6.84 per share on May 7, 2025, representing approximately 0.01% of the total issued shares of the Company as at the date of this announcement. It fully demonstrates Shanghai Medstar’s confidence in the future prospects of the Company and shows support to the Company’s continuous development.

As advised by Shanghai Medstar, it is confident in the business prospects and growth of the Group. Subject to compliance with applicable laws and regulatory requirements, Shanghai Medstar does not exclude the possibility of further increasing its shareholding in the Company by purchasing additional H shares of the Company from the open market at an appropriate time within six months from the date of this announcement.

We have been granted by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) a waiver from strict compliance with Rule 8.08(1)(a) of the Listing Rule so as to allow a lower public float percentage of between 15% and 25% (or such higher percentage as was held by the public upon completion of the listing of the shares of the Company on the Stock Exchange). Based on the information that is publicly available to the Company and to the best knowledge of its Directors, following the completion of the increase in shareholding and as at the date of this announcement, at least 20.94% of the Company’s total number of issued shares are held by the public.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Concord Healthcare Group Co., Ltd.
美中嘉和醫學技術發展集團股份有限公司
YANG Jianyu
Chairman and Executive Director

Beijing, the PRC, May 7, 2025

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. CHEN Hongzhang and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.